Histology-based treatment: A new scenario in the management of advanced nonsmall cell lung cancer

Current Opinion in Oncology

Volumn 21, Issue 2, 2009, Pages 97-98

  Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SMOKING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS;

EID: 62349111622     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328322ca04     Document Type: Editorial

References (12)

1. Kamangar F, Dore GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24:2137-2150.
2. Devesa SS, Bray S, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117:294-299.
3. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 2006; 11:533-538.
4. Gridelli C, Rossi A, Maione P. Treatment of nonsmall-cell lung cancer: state of the art and development of new biologic agents. Oncogens 2003; 22:6629-6638.
5. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall cell lung cancer. N Engl J Med 2006; 355:2542-2550.
6. Manegold C, von Pawel J, Zatloukal P, et al. BO17704 (AVAIL): a phase II randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent nonsquamous, nonsmall cell lung cancer (NSCLC) [abstract #LBA1]. Ann Oncol 2008; 19 (Suppl 8):viii1.
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2008; 26:3543-3551.
8. Peterson P, Park K, Fossella F. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? [abstract]. In: 12th World Conference on Lung Cancer; 2-6 September 2007; Seoul, Korea, pp. P2-P328.
9. Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008; 26:426s [abstract #8011].
10. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107:1589-1596.
11. Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, muticenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) [abstract #3]. J Clin Oncol 2008; 26 (Suppl 18):1006s.
12. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutation in EGFR in circulating lung-cancer cells. New Engl J Med 2008; 359:366-377.